MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance [Yahoo! Finance]
MaxCyte, Inc. (MXCT)
Company Research
Source: Yahoo! Finance
ROCKVILLE, MD, March 12, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its fourth quarter and full year ended December 31, 2023 financial results and reiterated its 2024 guidance. Fourth Quarter and Full Year Highlights Total revenue of $15.7 million in the fourth quarter of 2023, an increase of 26% over the fourth quarter of 2022. Core business revenue of $7.2 million in the fourth quarter of 2023, a decline of 32% over the fourth quarter of 2022. Strategic Platform License (SPL) Program-related revenue was $8.5 million for the fourth quarter of 2023, an increase of 359% over the fourth quarter of 2022. Total revenue of $41.3 million for the full year 2023, a decline of 7% over the full year 2022. Core business revenue of $29.8 mi
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- MaxCyte, Inc. (NASDAQ: MXCT) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $11.00 price target on the stock.MarketBeat
- We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024GlobeNewswire
- Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- MaxCyte signs strategic platform license with Be Biopharma [Seeking Alpha]Seeking Alpha
MXCT
Earnings
- 3/12/24 - Beat
MXCT
Sec Filings
- 5/1/24 - Form ARS
- 4/26/24 - Form DEF
- 3/28/24 - Form 4
- MXCT's page on the SEC website